Core Points - The company plans to repurchase shares amounting to no less than RMB 10 million and no more than RMB 15 million [1] - The source of funds for the repurchase will be the company's own funds and a special loan for share repurchase [1][7] - The repurchased shares will be used for employee stock ownership plans or equity incentives [1][5] - The maximum repurchase price is set at RMB 47.46 per share, which does not exceed 150% of the average trading price over the last 30 trading days prior to the board's decision [1][6] Repurchase Plan Details - The repurchase will be conducted through the Shanghai Stock Exchange trading system via centralized bidding [2][6] - The implementation period for the repurchase is within 12 months from the board's approval date [3][6] - There are currently no plans for share buybacks or sales by directors, supervisors, or senior management in the next three to six months [3][10] - The company has a shareholder, Bio-Ocean Group Co., Ltd., that is executing a disclosed share reduction plan [3][10] Financial Impact - The estimated repurchase amount of RMB 15 million represents approximately 0.41% of total assets, 0.91% of net assets, and 1.12% of current assets as of September 30, 2025 [8] - The company's debt-to-asset ratio is 54.42%, and the repurchase will not significantly impact its debt repayment ability [9] - The share repurchase is not expected to change the company's control structure or affect its listing status [9] Governance and Compliance - The proposal for the share repurchase was made by the chairman, Xianping Lu, based on confidence in the company's future and value [11][12] - The board's decision to repurchase shares was unanimously approved with 8 votes in favor [5] - The company has established a special securities account for the repurchase [18]
深圳微芯生物科技股份有限公司 关于以集中竞价交易方式回购股份的 回购报告书